Orexo AB (ORXOY) Q2 2026 Earnings Call Highlights: Strategic Advances Amidst Legal and ...

Orexo AB (ORXOY) showcases R&D progress and strategic collaborations while navigating legal hurdles and financial restructuring.

This article first appeared on GuruFocus. Release Date: July 16, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points - Orexo AB (ORXOY) has successfully completed an in vivo study for their 390 project, indicating progress in their R&D efforts. - The company is on track to file for ICPRI in Q3 and start a clinical trial in Q4, showing a clear timeline for product development. - Orexo AB (ORXOY) has initiated a scientific collaboration with an external pharmaceutical company, enhancing their R&D capabilities.

- The recruitment of a new head of business development, Ahila Nasaji, is expected to strengthen Orexo AB (ORXOY)'s business development efforts. - Orexo AB (ORXOY) has a cash position of 233 million, providing a financial cushion for ongoing and future projects. Negative Points - Orexo AB (ORXOY) is undergoing a transformation process, which has led to inflated operational expenses and cash flow issues.

- The company is facing legal challenges with the Department of Justice, which involves significant legal fees and potential settlements. - Orexo AB (ORXOY) has experienced low Abstral royalties due to expiring agreements and geopolitical issues in the Middle East. - The company is dealing with the impact of generic product launches in Canada, affecting EDRA royalties.

- Orexo AB (ORXOY) has incurred one-time costs related to exiting contracts and reducing staff, impacting their financial performance. Q & A Highlights Q: Can you provide more details on the progress with the DOJ process? A: Nicholas Sorensen, CEO: The DOJ process is ongoing, and we are working with various parties within the Department of Justice.

The main constituents are the Western District of Virginia. We can't disclose specific details, but the cost of running such a process could exceed $10 million. We are aiming for a settlement to avoid these costs and the risks associated with a court process.

Q: Are you done with the business restructuring, excluding the DOJ process? A: Nicholas Sorensen, CEO: We are nearly done with the restructuring. We have one person on a temporary contract in the US and one in Sweden.

We are also moving to a smaller office in Sweden to reduce expenses. No further supplier contracts need reviewing at this time. Q: Can you share insights from your recent meeting with the FDA regarding OX390?

A: Nicholas Sorensen, CEO: The FDA supported our preclinical work plan and suggested some additional activities. We are working with BARDA to cover these expenses. The FDA also initiated discussions on the clinical program, which is beneficial given the complexity of testing on end users.